Patent US5102876A successfully refreshed from Google Patents.
US5102876A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Reduction products of rapamycin
Assignee: Wyeth LLC
•
Filing: 1991-05-07
•
Granted: 1992-04-07
•
Expires: 2011-05-07
Abstract
Abstract Reduction of rapamycin with DIBAL furnishes either the 15-hydroxyrapamycin or 15,27-bis(hydroxy)rapamycin, depending upon the reaction conditions, having the general structure ##STR1## where Y is --CO-- --CH(OH)--. The compounds of this invention are useful in treating transplant rejection, host vs. graft disease, autoimmune diseases, diseases of inflammation, and fungal infections.
Inventors
- 👤 Craig E. Caufield
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 15:22
CPC Classifications
C; C07; C07D; C07D498/00; C07D498/12; C07D498/18
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
18 words
A compound of the formula ##STR5## where Y is --CO-- or --CH(OH)--, or a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
18 words
A compound of the formula ##STR5## where Y is --CO-- or --CH(OH)--, or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
9 words
A compound according to claim 1 which is 15-deoxo-15-hydroxyrapamycin.
Claim 4
Dependent Claim
9 words
A compound according to claim 1 which is 15,27-bis(deoxo)-15,27-bis(hydroxy)rapamycin.
Claim 5
Independent Claim
44 words
A method of treating transplantation rejection, host vs. graft disease, autoimmune diseases, and diseases of inflammation in a mammal by administering thereto an effective amount of a compound having the formula ##STR6## where Y is --CO-- or --CH(OH)--, or a pharmaceutically acceptable salt thereof.
Claim 6
Independent Claim
44 words
A method of treating transplantation rejection, host vs. graft disease, autoimmune diseases, and diseases of inflammation in a mammal by administering thereto an effective amount of a compound having the formula ##STR6## where Y is --CO-- or --CH(OH)--, or a pharmaceutically acceptable salt thereof.
Claim 7
Independent Claim
33 words
A method of treating fungal infections in mammals by administering thereto an effective amount of a compound having the formula ##STR7## where Y is --CO-- or --CH(OH)--, or a pharmaceutically acceptable salt thereof.
Claim 8
Independent Claim
33 words
A method of treating fungal infections in mammals by administering thereto an effective amount of a compound having the formula ##STR7## where Y is --CO-- or --CH(OH)--, or a pharmaceutically acceptable salt thereof.
Claim 9
Dependent Claim
43 words
A pharmaceutical composition for treating transplantation rejection, host vs graft disease, autoimmune diseases, diseases of inflammation, and fungal infections comprising: a. a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and b. a pharmaceutical carrier.
Claim 10
Dependent Claim
11 words
A pharmaceutical composition according to claim 6 in unit dosage form.
References Cited (Backward Citations)
US3929992A
Cited
US3993749A
Cited
US4885171A
Cited
US4316885A
Cited
US4401653A
Cited
US4650803A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-04-07 | 1995-10-07 | 1996-04-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-04-07 | 1999-10-07 | 2000-04-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-04-07 | 2003-10-07 | 2004-04-07 | $7700.00 | Window Closed / Lapsed |